Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer

In recent years, Non-small cell lung cancer (NSCLC) has evolved into a prime example for precision oncology with multiple FDA-approved “precision” drugs. For the majority of NSCLC lacking targetable genetic alterations, immune checkpoint inhibition (ICI) has become standard of care in first-line tre...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Schatz, Stefanie, Falk, Markus, Jóri, Balázs, Ramdani, Hayat O., Schmidt, Stefanie, Willing, Eva-Maria, Menon, Roopika, Groen, Harry J. M., Diehl, Linda, Kröger, Matthias, Wesseler, Claas, Griesinger, Frank, Hoffknecht, Petra, Tiemann, Markus, Heukamp, Lukas C.
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7353063/
https://ncbi.nlm.nih.gov/pubmed/32599951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12061685
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires